Antiangiogenic Activity of Aganirsen in Nonhuman Primate and Rodent Models of Retinal Neovascular Disease after Topical Administration
Investigative Ophthalmology & Visual Science2012Vol. 53(3), pp. 1195–1195
Citations Over TimeTop 10% of 2012 papers
Frank Cloutier, Matthew S. Lawrence, Robin J Goody, Stéphanie Lamoureux, Salman Al-Mahmood, Sylvie Colin, Antoine Ferry, Jean-Pascal Conduzorgues, Amel Hadri, Claus Cursiefen, Patricia Udaondo, Eric Viaud, Éric Thorin, Sylvain Chemtob
Abstract
Topical application of aganirsen offers a safe and effective therapy for both choroidal and retinal neovascularization without preventing its normal vascularization. Together, these findings support the clinical testing of aganirsen for human retinal neovascular diseases.
Related Papers
- → Research the most frequent localization of choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD)(2020)1 cited
- → 585Radiation therapy for choroidal neovascularization (CNV) in age-related macular degeneration (AMD) (preliminary results)(1996)
- Risk factors for choroidal neovascularization (CNV) in the second eye of patients with age-related macular degeneration (AMD)(1997)
- Comparison Of Anti-mt1-mmp And Anti-vegf Therapy In Age-related Macular Degeneration (amd) Choroidal Neovascularization (cnv) Model(2011)
- Effect of Quercetin on Formation of Choroidal Neovascularization （CNV） in Age-related Macular Degeneration （AMD）(2011)